Revenue
2018
2019
2020
2021
2022
2023
2024
2025
AGIOS PHARMACEUTICALS, INC. (AGIO)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $54.0M | $36.5M | $26.8M | $14.2M | $0 | $0 | $117.9M | $94.4M | $43.0M | $69.9M | $59.1M | $65.4M | $25.5M | $25.1M | $21.8M |
| Research & development | $339.5M | $301.3M | $295.5M | $279.9M | $257.0M | $220.8M | $214.3M | $341.3M | $292.7M | $220.2M | $141.8M | $100.4M | $54.5M | $41.0M | $31.3M |
| Operating expenses | — | — | — | — | — | — | — | $456.9M | $363.8M | $270.9M | $177.8M | $119.5M | $64.4M | $48.1M | $38.5M |
| Operating income | −$472.1M | −$425.7M | −$391.5M | −$389.0M | −$378.4M | −$335.9M | −$316.3M | −$362.5M | −$320.8M | −$201.0M | −$118.7M | −$54.1M | −$38.9M | −$23.0M | −$16.6M |
| EBITDAderived | — | — | — | — | — | — | −$308.2M | −$355.3M | −$314.4M | — | — | — | — | — | — |
| Net income | −$412.8M | $673.7M | −$352.1M | −$231.8M | $1.60B | −$327.4M | −$411.5M | −$346.0M | −$314.7M | −$198.5M | −$117.7M | −$53.5M | −$39.4M | −$20.1M | −$23.7M |
| Basic EPSper diluted share | -$7.12 | $11.86 | -$6.33 | -$4.23 | $26.55 | -$4.74 | -$6.86 | -$6.03 | -$6.75 | -$5.07 | -$3.15 | -$1.59 | -$2.83 | -$8.02 | -$8.90 |
| Diluted EPSper diluted share | -$7.12 | $11.64 | -$6.33 | -$4.23 | $26.55 | -$4.74 | -$6.86 | -$6.03 | -$6.75 | -$5.07 | -$3.15 | -$1.59 | -$2.83 | -$8.02 | -$8.90 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 2, 2026Form 4 · 10b5-1 | Burns James WilliamChief Legal Officer | SellCommon stock | 3.3K | $34.71 | $113.8K | 49.3K |
| Apr 2, 2026Form 4 · 10b5-1 | Gheuens SarahChief Medical Officer | SellCommon stock | 2.9K | $34.71 | $102.0K | 80.3K |
| Apr 2, 2026Form 4 · 10b5-1 | Jones CeciliaChief Financial Officer | SellCommon stock | 3.1K | $34.71 | $109.0K | 55.0K |
| Apr 2, 2026Form 4 · 10b5-1 | Milanova TsvetaChief Commercial Officer | SellCommon stock | 3.3K | $34.71 | $113.2K | 46.8K |
| Apr 2, 2026Form 4 · 10b5-1 | Viswanadhan KrishnanChief Corp Dev & Strategy | SellCommon stock | 3.0K | $34.71 | $102.7K | 10.3K |